GSK

GSK Released EMBRACE a Phase 2b Clinical Trial Data of an Investigational Broadly Neutralising Antibody for HIV

By Editor's Desk
18 March 2025

The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.

Tag: GSK

GSK Released EMBRACE a Phase 2b Clinical Trial Data of an Investigational Broadly Neutralising Antibody for HIV

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement